Ask AI
Managing CDKi Therapy in HR Positive HER2 Negative BC

CE / CME

The APP’s Guide to Patient-Centered Management of CDK4/6 Inhibitor Therapy for HR+/HER2- Breast Cancer

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: October 03, 2025

Expiration: April 02, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Patient Case 1 (cont’d)



  • Sally started adjuvant abemaciclib 2 mo ago

  • She calls to report 7-8 episodes a day of diarrhea despite taking as-needed antidiarrheal medication that is difficult to predict

  • She says her weight is stable and that she is eating and drinking without problems

  • She also noted fatigue despite adequate sleep and is having trouble returning to work as a result

  • You ask her to stop taking abemaciclib until her symptoms are resolving

Once her diarrhea has resolved, what additional counseling would you provide for Sally as the most appropriate next step in her treatment?

2.

A 56-yr-old woman with HR+/HER2- metastatic breast cancer has been taking ribociclib with an aromatase inhibitor for 2 mo. At a follow-up visit, she reports ongoing fatigue and nausea and admits that she has missed several doses of ribociclib due to her symptoms. Laboratory values are within normal limits. In your current practice, how would you counsel this patient to improve her treatment adherence?

3.

A 72-yr-old with HR+/HER2- metastatic breast cancer is taking abemaciclib plus fulvestrant. At her 1-mo follow-up, she says she feels overwhelmed by the number of medications she’s taking and is also concerned about the out-of-pocket cost of her cancer treatment. She is thinking about stopping therapy. In your current practice, how would you counsel this patient?